Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban

Prediction of Creatinine Clearance from Serum Creatinine

Donald W. Cockcroft, Henry Gault · ˜The œNephron journals/Nephron journals · 2008 · 15.4K citations

Pharmacy, Nephrology, Pharmacokinetics +15

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine · 2011 · 9.4K citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

Ron Pisters, Deirdre A. Lane, Robby Nieuwlaat et al. · CHEST Journal · 2010 · 4.5K citations · Full text

Medicine, Cardiology, Risk Assessment +14

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

Dagmar Kubitza, Michael Becka, Barbara Voith et al. · Clinical Pharmacology & Therapeutics · 2005 · 652 citations

Medicine, Pharmacokinetics, Pharmacology +16

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

Dagmar Kubitza, Michael Becka, Georg Wensing et al. · European Journal of Clinical Pharmacology · 2005 · 648 citations

Medicine, Pharmacokinetics, Pharmacology +5